Key Takeaways
- Volume-led record quarter: Revenue hit ₹308 crores on 42% YoY volume growth, while EBITDA margin jumped from 17% to 24% as operating leverage kicked in and new products contributed.
- Capex doubled, ambition raised: FY27 capex revised to ₹250 crores for two new buildings at Pakhajan, and the FY28 revenue target moved to more than ₹1,600 crores.
- The formula-driven model is a two-way street: Long-term contracts now exceed 50% of sales, locking in stable margins but also requiring price cuts when raw materials fall, a trade-off management accepts as the cost of predictability.
- Balance sheet healing fast: Net debt to EBITDA improved from 3.75x to 1.86x in a single quarter, and credit ratings were upgraded to A-, giving headroom for the expanded build-out.
- What to watch next quarter: Whether the 75% utilization target stays on track, how much of the ₹250 crore capex actually gets deployed, and whether supply-chain bottlenecks ease enough to stop eating into delivery timelines.
Volume Surge & Margin Recovery
- 42% volume jump drove the quarter: Revenue growth of 60% YoY split into roughly 42% volume and 17-18% price, with management explicit that performance came from selling higher quantity rather than better realization of old stock.
- Utilization moved the margin needle: Company-level capacity utilization rose from ~50% to 65%, and management expects the move toward 75% to cut costs and improve margins automatically through operating leverage.
- New products carry structurally better margins: Products launched in the last 12 months deliver 10-12% better margins than the legacy portfolio, and their growing offtake was a direct contributor to the quarter's margin expansion.
- Export is the growth engine: Exports contributed ~69% of revenue and are growing faster than domestic sales, which still grew ~10% YoY but at a slower pace, causing a mix shift toward the 70-75% export range management expects to sustain.
- Asia and Africa are the new battlegrounds: Management is making inroads into markets previously dominated by Asian majors; margins there are at par or slightly lower but not alarmingly so.
- Supply-chain friction is real and rising: Raw material supply issues and export container booking delays of 3-4 weeks are stretching the logistics team, a constraint that did not exist at this intensity before.
Parag Jhaveri: "Our team is, I will say, working hard, but they are struggling a lot for day to day, which was not the case. Also, our logistics team is struggling in getting export container booking, which is also a challenge lately."
The Pricing Model: Formula-Driven Stability
- Prices are tied to raw material cost, not market swings: With long-term suppliers and marquee customers, pricing is formula-driven, so raw material increases yield better realization and decreases require price reductions, a mechanism management calls "very simple theory."
- EBITDA percentage stays constant, not per-kg margin: Under the formula-driven model, the EBITDA percentage remains stable through raw material cycles, insulating the P&L from input-cost volatility at the expense of upside when spot prices spike.
- The shift from spot to contract is structural: Spot selling has fallen from 30-40% of revenue, and long-term contractual pricing now accounts for more than 50%, replaced by contractual long-term supply agreements that provide volume visibility and margin stability.
- Quarterly pricing discipline: The company is firm on quarterly pricing with customers, and price direction awareness helped navigate Q1 and six-month negotiations.
Parag Jhaveri: "It's not a market-driven price, but it's a formula-driven price. So, price goes up, we get better realization and price goes down, we have to reduce the price. It's as simple as that. Very simple theory here."
Capex & Capacity: Building Ahead of Demand
- Capex doubled mid-year: FY27 capex guidance was revised from ₹125 crores to ₹250 crores, directed toward two new production buildings at the Pakhajan facility for high-potential R&D-developed products.
- Phased delivery with fast ramp expectations: Phase 1 (₹100 crores) is targeted operational by Q1 FY28, Phase 2 (₹150 crores) by Q4 FY28, with construction taking a minimum of 15 months from now.
- Asset turn of ~2.5x is the planning assumption: Management expects the full ₹250 crore capex to generate ~2.5x revenue potential, implying roughly ₹625 crores of incremental revenue at peak utilization.
- 60-65% of new capacity already has customer coverage: Customers are identified and committed for the majority of the new facility's capacity, with the balance still to be sourced, reducing but not eliminating the commercialization risk.
- The build-ahead philosophy: Management starts construction before hitting utilization ceilings, wanting additional capacity available before touching the roof on existing plants.
- FY28 revenue target excludes the new buildings: The revised ₹1,600+ crore FY28 target does not include revenue from the two buildings commissioning in FY28, implying upside if Phase 1 ramps faster than conservatively modeled.
Parag Jhaveri: "Before we touch the roof, we want to have additional capacity available already for us. So, that was our reason to start construction of the two buildings simultaneously."
New Products & R&D: The Growth Backbone
- New chemistry drove all the growth from ₹600 to ₹850 crores: Over the last two years, ~30% of revenue came from new product lines, and management states that whatever new realization comes will "definitely come from new chemistry only."
- R&D is now consolidated at Pakhajan: The pilot facility started at Pakhajan to support R&D scale-up, while the Vapi R&D facility was shut and all efforts diverted to the new site, a move that helped win new marquee customers who visited the facility.
- New molecules start at ₹50-100 crores revenue each: Management will assess market response before committing to further capacity increases, keeping the initial bet measured.
- Diversification across chemistries is the hedge: R&D continuously works on opportunities across rubber, lubricant, and performance chemicals segments, so a headwind in one vertical does not stall the whole portfolio.
Balance Sheet & Credit Profile
- Leverage collapsed in a single quarter: Net debt to EBITDA improved from 3.75x at Q4 FY26 end to 1.86x, driven by higher operating earnings, improved profitability, and disciplined financial management.
- Credit ratings upgraded: CRISIL and ICRA upgraded bank loan ratings from BBB+ to A- during the quarter, lowering the cost of the ~₹100 crores in borrowings expected to be raised during FY27 to fund expansion.
- Working capital tightened materially: The cycle improved from 190 days to 143 days due to better inventory planning, improved receivables management, and tighter cash deployment control, though part of the inventory reduction came from raw material supply issues rather than pure efficiency.
Competitive Position & End-Market Risks
- Chinese capacity additions are not seen as a threat: Management argues that with a ₹1,200-1,500 crore addressable market and a $200-300 million aspiration, Chinese overcapacity is not a binding constraint, and customers are always looking for an alternate supply chain.
- EV risk is a 15-20 year problem, not a 10-year one: On the lubricant exposure, management sees EVs becoming a fit only after 15-20 years and perceives no threat within a 10-year horizon, a stance that leaves the medium-term lubricant thesis intact but unexamined beyond that window.
- Market share gains are real but unattributed: When asked from whom the company is gaining share, management candidly stated they do not know whom they are replacing, an admission that the growth is visible but its competitive source is not tracked.
- The US business is back after tariff resolution: Tariff issues in the USA have been resolved and sales to the US increased sizably, with the subsidiary picking up well.
Parag Jhaveri: "That's of 1,200 crore to 1,500 crore addressable market, we are aspire to become $200-$300 million. I don't see that as a challenge. And always the customers are looking for an alternate supply chain."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | More than ₹1,600 crores (excludes new buildings) | FY28 |
| Annual revenue growth | 30% to 40% | Next few years |
| EBITDA margin | Endeavor to maintain current-quarter level | FY27 |
| Capacity utilization | Reach 70% company-level | End of FY27 |
| Phase 1 capex operational | ₹100 crores, ~2x asset turn revenue potential | Q1 FY28 |
| Phase 2 capex operational | ₹150 crores | Q4 FY28 |
| Phase 1 revenue contribution | "Try our best" to get ₹100 crores | FY28 |
| Export mix | Sustain at 70-75% | Ongoing |
| Borrowings for expansion | ~₹100 crores | FY27 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹308 cr, highest quarterly revenue, +60% YoY |
| Volume growth | 42% YoY |
| EBITDA | ₹74.42 cr |
| EBITDA margin | 24.2%, up from 17% in prior period |
| PAT | ₹36 cr |
| PAT margin | 11.7% |
| FY28 revenue target | >₹1,600 cr, revised upward |
| Annual revenue growth target | 30% to 40% over the next few years |
| Export contribution | ~69% of total revenue |
| Industrial chemicals contribution | ~89% of total revenue |
| Capacity utilization | >65%, company level, up from ~50% |
| Net debt to EBITDA | 1.86x as of June 30, 2026, improved from 3.75x at Q4 FY26 end |
| Working capital cycle | 143 days, improved from 190 days |
| FY27 capex plan | ₹250 cr, revised from ₹125 cr |
| Q1 FY27 capex incurred | ₹18.73 cr |
| Long-term contractual pricing customers | >50% of revenue, up from 30%–40% in the past |
| Bank loan ratings | A-, upgraded from BBB+ by CRISIL and ICRA |